Business
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed A...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting\nPhase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT™ study dataBria-OTS+™ in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701 PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), and two posters highlighting further analyses of Phase 2 data. Abstracts will be published in the online Proceedings of the AACR. “Standards of care in cancer are evolving rapidly as innovative immunotherapy approaches emerge with potentially better safety profiles than chemotherapy. Clinical data, including BriaCell’s, highlight that maintaining quality of life is an important treatment goal alongside efficacy and safety,” stated lead author, Saranya Chumsri, MD, Principal Investigator of BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology, Mayo Clinic. “At BriaCell, we are focused on bringing novel therapeutics to cancer patients with unmet medical needs with the ultimate goal of improving patients’ lives,” noted William V. Williams, MD, BriaCell’s President & CEO. “Our new quality of life data from the Phase 3 Bria-IMT + CPI study in patients with metastatic breast cancer who failed prior therapies show very positive trends, bringing us one step closer to transforming care for these patients.” Session T...